Dmitry Balyasny’s DiaMedica Therapeutics DMAC Stock Holding History

Dmitry Balyasny’s Portfolio DMAC Stock Details DMAC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-17,086	Closed	-$136K	–	3021
2025 Q4	$136K	Buy	+17,086	New	+$128K	﹤0.01%	2934
2025 Q2	–	Sell	-25,270	Closed	-$95.8K	–	2937
2025 Q1	$95.8K	Buy	25,270 +10,689	+73%	+$61.1K	﹤0.01%	2685
2024 Q4	$79.2K	Buy	+14,581	New	+$68.8K	﹤0.01%	2620

Other funds holding DMAC

CLG

Cooperman Leon G $3.55B AUM 41.85% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

PAPAIJV

Paragon Associates & Paragon Associates II Joint Venture Dallas, Texas $73.6M AUM 61.93% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

First Manhattan New York $39.2B AUM 21.04% 1-Year Est. Return

Bleichroeder LP New York $559M AUM 83.7% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Dmitry Balyasny's DMAC Position: Q1 2026 in Review

Dmitry Balyasny sold out of DiaMedica Therapeutics (DMAC) in Q1 2026, closing a stake of 17,086 shares — an estimated $136K sold.

Dmitry Balyasny first reported a position in DMAC in Q4 2024 and held it in 3 quarters. The position peaked at $136K in Q4 2025. 99 funds tracked by Wall St. Rank hold DMAC as of Q1 2026.

Dmitry Balyasny reported no remaining DiaMedica Therapeutics position as of Q1 2026 after selling out during the quarter.
Dmitry Balyasny sold 17,086 DiaMedica Therapeutics shares in Q1 2026, an estimated $136K.
Dmitry Balyasny first reported a position in DiaMedica Therapeutics in Q4 2024 and held it in 3 quarters.
Dmitry Balyasny's DiaMedica Therapeutics position peaked at $136K in Q4 2025.
99 funds tracked by Wall St. Rank held DiaMedica Therapeutics as of Q1 2026.

Based on Balyasny Asset Management's 13F filing for Q1 2026, filed 15 May 2026.